Baker Brothers Affiliate Files to Sell $26.8M in Celcuity Stock on FDA Approval Day
CELC has more than doubled off its 52-week low of $13.365.
Summary
Former affiliate 667, L.P. (Baker Brothers) filed to sell 261,368 shares (~$26.8M) of Celcuity on the day the FDA approved gedatolisib. Combined with a related filing, total proposed sales reach 3.1M shares.
Key Events · Ownership and Investor Activity · CELC
-
Former Affiliate Sells on FDA Approval Day
667, L.P., a Baker Brothers affiliate, filed to sell 261,368 shares (~$26.8M) on July 14, 2026, the same day the FDA approved gedatolisib for HR-positive, HER2-negative breast cancer.
-
Combined Sales Total 3.1M Shares
A separate filing by Baker Brothers Life Sciences, L.P. for 2,838,632 shares brings the total proposed sale by the group to 3,100,000 shares.
-
No Prior Sales in Past 3 Months
The filing reports no sales by 667, L.P. in the prior three months, indicating this is a new decision to reduce exposure rather than a continuation of an ongoing program.
-
Timing Raises Conviction Questions
The sale comes immediately after the most significant regulatory milestone in Celcuity's history, potentially signaling a 'sell the news' stance by a sophisticated biotech investor.
Analysis · CELC · Industrial Applications And Services
On the same day the FDA approved Celcuity's breast cancer drug gedatolisib, former affiliate 667, L.P. — part of the Baker Brothers investment group — filed to sell 261,368 shares worth approximately $26.8 million. Combined with a separate filing by Baker Brothers Life Sciences, L.P., the total proposed sale is 3.1 million shares. While the sale represents less than 1% of the company's $5.4 billion market cap, the timing — immediately after the most significant regulatory milestone in the company's history — raises questions about the conviction of a sophisticated biotech investor. The filing does not indicate whether this is a pre-planned 10b5-1 sale, but the lack of any prior sales in the past three months suggests this is a new decision to reduce exposure at a moment of peak news flow.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CELC was trading at $111.05 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $13.37 to $151.02. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.